Indeed, more studies are needed to test whether the usage of nonselective β-blockers (blocking β2-AR in skeletal muscle) in HF therapy would be beneficial or detrimental to counteract skeletal myopathy. This evidence concerns the gene ADRB2 and skeletal muscle disorder.